OVIDREL

This brand name is authorized in Australia, Brazil, Canada, Ecuador, Hong Kong, Japan, New Zealand, Singapore, United States

Active ingredients

The drug OVIDREL contains one active pharmaceutical ingredient (API):

1 Choriogonadotropin alpha UNII 6413W06WR3 - CHORIOGONADOTROPIN ALFA

The principal pharmacodynamic activity in women is oocyte meiosis resumption, follicular rupture (ovulation), corpus luteum formation and production of progesterone and estradiol by the corpus luteum. Read about Choriogonadotropin alpha

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
OVIDREL Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/Old

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
G03GA08	Choriogonadotropin alfa	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03G Gonadotropins and other ovulation stimulants → G03GA Gonadotropins
Discover more medicines within G03GA08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 6182J
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 525413070044403
Country: CA	Health Products and Food Branch	Identifier(s): 02262088, 02371588
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 26.642-10-05
Country: HK	Department of Health Drug Office	Identifier(s): 52881, 62021
Country: JP	医薬品医療機器総合機構	Identifier(s): 2413406G1020
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 11387
Country: SG	Health Sciences Authority	Identifier(s): 13015P
Country: US	FDA, National Drug Code	Identifier(s): 44087-1150